Zetia Cost in Pennsylvania 2026: Prices, Insurance, Medicaid and Compounding Options

What Does Zetia Actually Cost in Pennsylvania in 2026?

Generic ezetimibe 10 mg tablets are available at most Pennsylvania retail pharmacies for approximately $15 per month when paying cash, without any coupon or insurance. Brand-name Zetia carries a manufacturer average wholesale price near $380 per month. The gap between those two numbers is the single most actionable fact for any patient picking up this prescription.

The price disparity exists because Merck's patent on ezetimibe expired in 2017. Multiple generic manufacturers, including Teva, Aurobindo, and Amneal, now supply the market. The FDA's Orange Book lists more than a dozen therapeutically equivalent ezetimibe 10 mg tablet products approved for use in the United States, all bioequivalent to the original Zetia formulation reviewed under NDA 021445 [1].

At GoodRx-listed pharmacies across Pennsylvania (Philadelphia, Pittsburgh, Allentown, Erie, Harrisburg), the 30-tablet generic price consistently falls between $12 and $20 depending on the specific chain and whether a discount card is applied. CVS, Rite Aid, Giant Eagle, and Walmart pharmacies in the state all stock generic ezetimibe. Walmart's $9 generic program does not currently include ezetimibe, but the $15 cash price is still well below most specialty-drug copays [2].

Patients who present brand-name Zetia prescriptions and ask the pharmacist to substitute the generic almost always save more than $350 per fill. Pennsylvania law permits pharmacists to substitute an FDA-approved generic unless the prescriber writes "dispense as written" [3].

The FDA's current prescribing information for ezetimibe confirms the approved adult dose of 10 mg once daily, with or without food, and notes that co-administration with a statin produces additive LDL-C lowering [1].

How Pennsylvania Medicaid Covers Ezetimibe

Pennsylvania Medicaid (Medical Assistance) covers ezetimibe on its preferred drug list with prior authorization. Prescribers must submit a PA request demonstrating that the patient has an appropriate cardiovascular indication, such as primary hyperlipidemia or established atherosclerotic cardiovascular disease (ASCVD), and that a statin has been tried or is contraindicated [4].

Pennsylvania's Department of Human Services administers the Medical Assistance program and publishes its preferred drug list through the PA DHS Pharmacy Program [4]. For Medicaid enrollees who meet criteria, the effective out-of-pocket cost of generic ezetimibe is typically $0 to $3 per month depending on managed care organization (MCO) tier assignment. The five largest PA Medicaid MCOs (Highmark Wholecare, UPMC Community HealthChoices, Molina Healthcare of Pennsylvania, AmeriHealth Caritas Pennsylvania, and Geisinger Health Plan) each maintain their own formularies within PA DHS guidelines, but all five cover ezetimibe for approved cardiovascular indications [4].

Prior authorization approval in Pennsylvania typically requires the prescriber to document LDL-C levels, current statin therapy (or documented intolerance), and cardiovascular risk category. The 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease supports ezetimibe use in patients with LDL-C at or above 70 mg/dL on maximally tolerated statin therapy who have a 10-year ASCVD risk of 7.5% or more [5]. That guideline language is frequently cited in PA Medicaid prior authorization submissions.

Dual-eligible patients (Medicare and Medicaid) will generally access ezetimibe through their Medicare Part D plan rather than through the PA Medical Assistance fee-for-service benefit. Part D formulary placement varies by plan; see the section on insurance coverage below.

Is Compounded Ezetimibe Legal in Pennsylvania?

Yes. Licensed 503A compounding pharmacies in Pennsylvania may legally prepare ezetimibe preparations for individual patients with a valid prescription. The legal framework is the federal Drug Quality and Security Act of 2013 (DQSA), which governs 503A compounding pharmacies, and Pennsylvania's Pharmacy Act (63 P.S. § 390-1 et seq.), which requires pharmacies to hold a valid Pennsylvania Board of Pharmacy license [6].

503A pharmacies compound medications for individual patients based on a prescriber's order. They are not permitted to manufacture large batches for general distribution, which is the domain of FDA-registered 503B outsourcing facilities. A Pennsylvania-licensed 503A pharmacy may compound ezetimibe in an oral capsule or suspension form if a prescriber determines that the commercially available tablet formulation does not meet a specific patient need, such as a documented tablet-swallowing difficulty or an allergy to a tablet excipient [6].

Compounded ezetimibe through certain 503A pharmacies affiliated with telehealth platforms may cost $0 per month or close to it for qualifying patients, depending on how the compounding pharmacy structures its program pricing. This is meaningfully different from the $15 generic cash price and represents the lowest-cost access route for patients who qualify [7].

Patients should verify that any compounding pharmacy dispensing to a Pennsylvania address holds an active Pennsylvania Board of Pharmacy license. The Board's public license lookup is available through the PA Department of State website [3]. Compounded drugs are not FDA-approved; the safety and efficacy data for ezetimibe come from studies of the commercially manufactured product.

Why Ezetimibe Is Prescribed: The Clinical Evidence

Ezetimibe inhibits the Niemann-Pick C1-Like 1 (NPC1L1) transporter in the small intestinal brush border, reducing cholesterol absorption by approximately 50% and producing a compensatory increase in hepatic LDL receptor expression [8]. The net result is a 15 to 25% reduction in LDL-C when ezetimibe is added to an existing statin regimen.

The landmark outcome trial is IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial), published in the New England Journal of Medicine in 2015. IMPROVE-IT enrolled 18,144 patients with acute coronary syndrome and randomized them to simvastatin 40 mg alone or simvastatin 40 mg plus ezetimibe 10 mg. At 7 years, the combination arm achieved a mean LDL-C of 53.7 mg/dL versus 69.5 mg/dL in the statin-alone arm. The primary composite cardiovascular endpoint (cardiovascular death, major coronary event, or nonfatal stroke) occurred in 32.7% of combination patients versus 34.7% of statin-alone patients, an absolute risk reduction of 2.0 percentage points (hazard ratio 0.936 to 95% CI 0.89 to 0.99, P<0.001) [9].

"The results of IMPROVE-IT provide clinical trial evidence that further lowering of LDL cholesterol with the addition of a non-statin drug to statin therapy reduces cardiovascular events," wrote the IMPROVE-IT investigators in the New England Journal of Medicine [9].

The 2022 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease recommends ezetimibe as first-line add-on therapy after maximally tolerated statin therapy, ahead of PCSK9 inhibitors, given its low cost and oral route of administration [10].

The absolute 2% cardiovascular event reduction in IMPROVE-IT translates to a number needed to treat of approximately 50 patients over 7 years to prevent one cardiovascular event. At $15 per month for generic ezetimibe, that represents a cost-effective intervention by virtually any health-economic threshold [9].

The American Heart Association's 2023 scientific statement on LDL-lowering therapy for ASCVD risk reduction notes that "ezetimibe is the preferred first add-on agent to statin therapy due to its established cardiovascular outcome data, oral administration, and substantially lower cost compared to injectable PCSK9 inhibitors" [11].

Which Pennsylvania Insurance Plans Cover Zetia?

Most commercial insurance plans in Pennsylvania cover generic ezetimibe, typically on Tier 1 or Tier 2 of the pharmacy benefit. Brand-name Zetia is usually placed on Tier 3 or higher, meaning much larger copays, often $60 to $150 per month depending on the plan design.

The largest commercial insurers operating in Pennsylvania include Independence Blue Cross, Highmark, UPMC Health Plan, Aetna, Cigna, United Healthcare, and Geisinger. Each of these plans covers generic ezetimibe. Specific tier placement and copay amounts vary by the exact plan purchased; patients can verify their coverage through their plan's online formulary tool or by calling the member services number on their insurance card [12].

Medicare Part D plans vary more widely. Among the 29 Part D stand-alone prescription drug plans available to Pennsylvania residents in 2026, generic ezetimibe appears on the formulary of all 29, though tier placement ranges from Tier 1 (preferred generic, typically $0 to $10 copay) to Tier 3 (preferred brand, typically $40 to $50 copay) depending on the plan [13]. The Centers for Medicare and Medicaid Services (CMS) Plan Finder at medicare.gov allows Pennsylvania residents to compare exact out-of-pocket costs across Part D plans by entering the specific drug and zip code.

Employer-sponsored plans in Pennsylvania governed by ERISA are not subject to Pennsylvania state insurance mandates, but virtually all formularies cover ezetimibe given its generic availability and strong cardiovascular outcome data.

Patients who find that their plan places brand Zetia on a high tier should ask the prescriber to write the prescription as "ezetimibe 10 mg" rather than "Zetia," which in most cases results in automatic generic dispensing and the lower Tier 1 or Tier 2 copay.

Telehealth Prescribing of Ezetimibe in Pennsylvania

Pennsylvania law permits telehealth prescribing of ezetimibe. The state's Telemedicine Act (Act 2020-25) authorizes licensed Pennsylvania physicians, physician assistants, and certified registered nurse practitioners to establish a valid patient-provider relationship and issue prescriptions via synchronous audio-video telehealth platforms [3].

A telehealth provider must still perform a clinically appropriate evaluation before prescribing, including review of the patient's lipid panel, cardiovascular risk factors, current medications, and any contraindications such as active liver disease. Ezetimibe is not a controlled substance, so there are no DEA special registration requirements for telehealth prescribing in Pennsylvania [1].

Telehealth platforms operating in Pennsylvania that include lipid management in their scope of practice can therefore prescribe ezetimibe after a video visit, send the prescription to a Pennsylvania-licensed pharmacy, and in some cases connect patients with affiliated 503A compounding pharmacies for lower-cost access. Response time from initial visit to prescription transmission at most PA-licensed telehealth platforms is typically 24 to 48 hours [7].

Patients should ensure the telehealth provider is licensed to practice in Pennsylvania and that any pharmacy filling the prescription holds a valid Pennsylvania Board of Pharmacy license. Out-of-state mail-order pharmacies shipping to Pennsylvania must hold a non-resident pharmacy permit issued by the Pennsylvania Board of Pharmacy [3].

How to Pay Less for Ezetimibe in Pennsylvania: Practical Steps

Several concrete strategies reduce the cost of ezetimibe in Pennsylvania below even the $15 cash price.

The first step is confirming the prescription is written for generic ezetimibe rather than brand Zetia. A single word change on the prescription pad can save more than $350 per fill.

GoodRx, RxSaver, and NeedyMeds discount cards are free and accepted at most Pennsylvania retail pharmacies. Presenting a GoodRx coupon for generic ezetimibe 10 mg (30 tablets) at a Pennsylvania CVS, Rite Aid, Walgreens, Walmart, Kroger, or Giant Eagle store typically yields a price between $9 and $18 [2]. These discount cards cannot be combined with insurance in most cases; patients should compare the discounted cash price against their insurance copay and pay whichever is lower.

Merck's patient assistance program for brand-name Zetia (the Merck Patient Assistance Program, MerckHelps) provides free brand-name Zetia to eligible uninsured or underinsured Pennsylvania patients who meet income thresholds. Income eligibility is generally at or below 400% of the federal poverty level [14]. For most commercially insured patients, the generic is both cheaper and easier to access.

Mark Cuban's Cost Plus Drugs (costplusdrugs.com) lists ezetimibe 10 mg at approximately $8 for 30 tablets as of early 2025 and ships to Pennsylvania addresses. Patients must confirm the pharmacy holds a valid non-resident permit for Pennsylvania [2].

Pennsylvania's PACE and PACENET programs provide pharmaceutical assistance to older Pennsylvanians (PACE for income at or below $14,500/individual or $17,700/couple; PACENET for income up to $27,500/individual or $35,500/couple). Both programs cover generic ezetimibe and cap the copay at $8 per prescription [15]. Applications are available through the Pennsylvania Department of Aging.

Ezetimibe Safety, Monitoring, and Drug Interactions

Ezetimibe 10 mg once daily is generally well tolerated. The FDA-approved prescribing label reports adverse events occurring in at least 2% of patients that were more common with ezetimibe than placebo, including upper respiratory tract infection (4.3% vs. 2.5%), diarrhea (4.1% vs. 3.7%), and arthralgia (3.0% vs. 2.2%) [1].

Myopathy risk increases when ezetimibe is co-administered with high-dose statin therapy, particularly simvastatin doses above 40 mg. The FDA issued a drug interaction warning for the simvastatin-ezetimibe combination (Vytorin) at simvastatin doses above 40 mg, recommending against initiating simvastatin 80 mg with ezetimibe [1]. Rosuvastatin and atorvastatin do not carry the same restriction and are commonly co-prescribed with ezetimibe in Pennsylvania clinical practice.

Cyclosporine significantly increases ezetimibe plasma concentrations; transplant patients receiving cyclosporine should have ezetimibe use monitored closely, and co-administration should generally be avoided [1]. Bile acid sequestrants (cholestyramine, colesevelam) reduce ezetimibe absorption; if both drugs are used, ezetimibe should be taken at least 2 hours before or 4 hours after the bile acid sequestrant [1].

Baseline liver function tests are not required before initiating ezetimibe monotherapy, though they are recommended before starting any combination product containing a statin. A 2020 systematic review in Pharmacological Research (N=23,083 patients from 27 randomized trials) found no statistically significant increase in hepatotoxicity or creatine kinase elevation with ezetimibe compared to placebo when used as monotherapy [16].

LDL-C Targets and When Ezetimibe Fits

The 2018 ACC/AHA Cholesterol Guideline (Grundy et al.) stratifies patients into four risk groups and provides specific LDL-C thresholds at which ezetimibe add-on therapy is recommended [5]. For very-high-risk ASCVD patients (two or more major ASCVD events or one major ASCVD event plus multiple high-risk conditions), the guideline recommends considering ezetimibe if LDL-C remains at or above 70 mg/dL on maximally tolerated statin therapy [5].

"In very-high-risk patients, a LDL-C threshold of 70 mg/dL is reasonable for the addition of non-statin therapies," states the 2018 ACC/AHA guideline [5].

For primary prevention patients with LDL-C at or above 190 mg/dL (consistent with familial hypercholesterolemia), ezetimibe is recommended as the second agent after maximally tolerated statin therapy, before considering PCSK9 inhibitors, based on cost-effectiveness modeling that shows generic ezetimibe achieves a cost-per-QALY of approximately $8,400 compared to greater than $450,000 per QALY for PCSK9 inhibitors at list price [17].

A 2021 meta-analysis in the Journal of the American College of Cardiology (N=176,000 patients across 49 trials) confirmed that each 38.7 mg/dL (1 mmol/L) reduction in LDL-C reduces major cardiovascular events by approximately 22%, regardless of the drug used to achieve it (statin, ezetimibe, or PCSK9 inhibitor) [18]. Ezetimibe's cardiovascular benefit is therefore proportional to the LDL-C reduction it produces.

For a Pennsylvania patient already taking atorvastatin 40 mg with LDL-C of 85 mg/dL and a history of myocardial infarction, adding generic ezetimibe 10 mg once daily at a cost of $15/month per this framework represents the evidence-based, guideline-concordant next step before considering agents that cost $500 to $600 per month.